At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
ABBV-3067 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
In Brief
A Phase 2 clinical trial evaluating ABBV-3067, Placebo ABBV-3067, and 2 other interventions for Cystic Fibrosis. Completed, enrolled 78 participants across 51 sites in 12 countries.
Detailed Summary
This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesBelgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Serbia, Slovakia, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartDec 2019
Primary CompletionJun 2022
TodayJul 2026
First PostedMay 31, 2019
Enrollment StartDec 11, 2019
Primary CompletionJun 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.1 years ago
Interventions
ABBV-3067drug
Tablet taken orally.
Placebo ABBV-3067drug
Tablet taken orally.
ABBV-2222drug
Capsule taken orally.
Placebo ABBV-2222drug
Capsule taken orally.